Affordable Access

Access to the full text

Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report

Authors
  • He, Shu-Yan
  • Lin, Qing-Feng
  • Chen, Jie
  • Yu, Gui-Ping
  • Zhang, Jun-Ling
  • Shen, Dong
Type
Published Article
Journal
World Journal of Clinical Cases
Publisher
Baishideng Publishing Group Inc
Publication Date
Feb 26, 2021
Volume
9
Issue
6
Pages
1329–1335
Identifiers
DOI: 10.12998/wjcc.v9.i6.1329
PMID: 33644199
PMCID: PMC7896682
Source
PubMed Central
Keywords
Disciplines
  • Case Report
License
Green

Abstract

BACKGROUND The most common EGFR mutations are in-frame deletions in exon 19 and point mutations in exon 21. Cases with classical EGFR mutations show a good response to EGFR tyrosine kinase inhibitors (TKIs), the standard first-line treatment. With the development of next generation sequencing, some uncommon genomic mutations have been detected. However, the effect of TKIs on such uncommon EGFR mutations remains unclear. CASE SUMMARY Here, we report a case of rare EGFR co-mutation in non-small cell lung cancer and the efficacy of afatinib on this EGFR co-mutation. A 64-year-old woman was diagnosed with thoracolumbar and bilateral local rib bone metastases, bilateral pulmonary nodules, and pericardial and left pleural effusion. The pathological diagnosis was lung adenocarcinoma. To seek potential therapeutic regimens, rare co-mutation comprising rare EGFR G724S/R776H mutations and amplification were identified. The patient experienced a significant clinical response with a progression-free survival of 17 mo. CONCLUSION A case of non-small cell lung cancer with rare EGFR G724S / R776H mutations and EGFR amplification responds well to TKI treatment.

Report this publication

Statistics

Seen <100 times